variables: 817874
Data license: CC-BY
This data as json
id | name | unit | description | createdAt | updatedAt | code | coverage | timespan | datasetId | sourceId | shortUnit | display | columnOrder | originalMetadata | grapherConfigAdmin | shortName | catalogPath | dimensions | schemaVersion | processingLevel | processingLog | titlePublic | titleVariant | attributionShort | attribution | descriptionShort | descriptionFromProducer | descriptionKey | descriptionProcessing | licenses | license | grapherConfigETL | type | sort | dataChecksum | metadataChecksum |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
817874 | Share of new tested bacteriologically confirmed pulmonary tuberculosis patients that have rifampicin resistance | % | 2023-12-15 10:51:02 | 2024-07-25 22:54:12 | 2017-2022 | 6308 | % | { "unit": "%", "shortUnit": "%", "numDecimalPlaces": 0 } |
0 | rr_share | grapher/tuberculosis/2023-11-27/drug_resistance_surveillance/drug_resistance_surveillance#rr_share | 2 | major | Share of new tested bacteriologically confirmed pulmonary tuberculosis patients that have rifampicin resistance. Rifampicin is an antibiotic medication used primarily in the treatment of tuberculosis and other bacterial infections; it works by inhibiting the growth of bacteria. | [] |
float | [] |
f1b86f41e863f8603400a17f8844270b | 391fae39275a366366c682eda1f7365c |